Dendritic Cell-Based Immunotherapy for Prostate Cancer. (4th November 2010)

• Record Type: Journal Article
• Authors: Jähnisch, Hanka; Füssel, Susanne; Kiessling, Andrea; Wehner, Rebekka; Zastrow, Stefan; Bachmann, Michael; Rieber, Ernst Peter; Wirth, Manfred P.; Schmitz, Marc
• Other Names: Liu Yang Academic Editor.
• Is Part Of: Clinical & developmental immunology. Volume 2010(2010)
• Publication Date: 2010-11-04
• Subjects: Developmental immunology -- Periodicals; Clinical immunology -- Periodicals; Immune System -- immunology -- Periodicals; Immune System -- growth & development -- Periodicals; Immune System Diseases -- immunology -- Periodicals; 571.9638
• DOI: 10.1155/2010/517493
• Languages: English
• ISSNs: 1740-2522

Abstract

Abstract : Dendritic cells (DCs) are professional antigen-presenting cells (APCs), which display an extraordinary capacity to induce, sustain, and regulate T-cell responses providing the opportunity of DC-based cancer vaccination strategies. Thus, clinical trials enrolling prostate cancer patients were conducted, which were based on the administration of DCs loaded with tumor-associated antigens. These clinical trials revealed that DC-based immunotherapeutic strategies represent safe and feasible concepts for the induction of immunological and clinical responses in prostate cancer patients. In this context, the administration of the vaccine sipuleucel-T consisting of autologous peripheral blood mononuclear cells including APCs, which were pre-exposed in vitro to the fusion protein PA2024, resulted in a prolonged overall survival among patients with metastatic castration-resistent prostate cancer. In April 2010, sipuleucel-T was approved by the United States Food and Drug Administration for prostate cancer therapy.